Reason for request
Inclusion on the list of medicines reimbursed by National Insurance and approved for use by hospitals in the extension of indication “treatment of locally advanced prostate cancer”.
The actual benefit of ENANTONE is substantial.
Clinical Added Value
|no clinical added value||
ENANTONE SR 3.75 mg and 11.25 mg, do not improve actual benefit (level V) compared to other GnRH analogues in the treatment of locally advanced prostate cancer.
Évaluation des médicaments